NASDAQ:VTRS
Viatris (VTRS-Q)
Financials
Technical Analysis
Related posts
Nervous markets await Nvidia
Apr 16, 2025, 12:00 amThis summary was created by AI, based on 6 opinions in the last 12 months.
Viatris (VTRS-Q) has been a mixed bag for investors. While the stock has experienced a significant drop of around 15% following weak earnings, it is generating substantial free cash flow, which should be redirected towards share buybacks at an attractive valuation. Analysts emphasize the stock’s low price-to-earnings ratio of around 5x, suggesting it is quite cheap, with some experts predicting a target price of $20. Despite its challenges, including an investigation affecting an EBITDA of $300-400M, the 4% dividend yield offers stability. With a market cap of $12B, the company is seen as under-researched and is pursuing multiple avenues such as debt reduction, acquisitions, and share repurchases.
Premium contentOur PAST TOP PICK with VTRS has triggered its stop at $11.50. To remain disciplined we recommend covering the position at this time. Along with previous recommendations, this will result in a net investment gain of 4%.
Premium contentPremium contentWe reiterate VTRS, producer of Lipitor as one of its brands, as a TOP PICK. Management has simplified its product offering portfolio and committed to returning half of free cash cash flow to shareholders through aggressive share buybacks. It trades at 8x earnings and below book value. Cash reserves are growing as debt is aggressively retired. Its dividend is backed by a payout ratio under one-third of cash flow. We recommend trailing up the stop (from $8.50) to $10.50, looking to achieve $14 -- upside potential of 19%. Yield 4.0%
(Analysts’ price target is $14.13)Premium contentThe pharma company produces Lipitor as one of its brands. It has embarked on a divestiture strategy that is allowing it to focus on core competencies and reduce costs. The are on target for $450 million in new product launches. It trades at 7x earnings and below book value. Cash reserves are growing as debt is aggressively retired. Its dividend is backed by a payout ratio under one-third of cash flow. We recommend placing a stop-loss at $8.50, looking to achieve $41 -- upside potential of 30%. Yield 4.5%
(Analysts’ price target is $14.11)It is the cheapest stock in their portfolio at 4X earnings, a pharma company formed by a joint venture. Its investment grade bond issues are in rock solid shape. It sold a division for $2 billion and will use the cash for a couple of acquisitions in eye wear and to buy back stock. There are potential sales of other smaller divisions so there could be more buybacks plus paying down debt. The dividend yield is 4.1%. Has a low price due to a couple of disappointing quarters but numbers have been solid since. Also revenues have been flat-lining.
Buy 4 Hold 10 Sell 0
Viatris(VTRS-Q) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 2
Neutral - Hold Signals / Votes : 2
Bearish - Sell Signals / Votes : 2
Total Signals / Votes : 6
Viatris(VTRS-Q) Frequently Asked Questions
What is Viatris stock symbol?
Viatris is a American stock, trading under the symbol VTRS-Q on the NASDAQ (VTRS). It is usually referred to as NASDAQ:VTRS or VTRS-Q
Is Viatris a buy or a sell?
In the last year, 6 stock analysts published opinions about VTRS-Q. 2 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Viatris.
Is Viatris a good investment or a top pick?
Viatris was recommended as a Top Pick by on . Read the latest stock experts ratings for Viatris.
Why is Viatris stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Viatris worth watching?
6 stock analysts on Stockchase covered Viatris In the last year. It is a trending stock that is worth watching.
What is Viatris stock price?
On 2025-07-03, Viatris (VTRS-Q) stock closed at a price of $9.3.
Proof that not every stock he buys goes up ;) He's held for years. Recent earnings were weak, and stock fell ~15%. Generating significant free cashflow, which now will be used to buy back shares incredibly cheaply. It's the best use of capital at this time. FDA investigation in one of their plants, costing about $300-400M in EBITDA. Yield is 4+%.